Talacotuzumab

DB14796InvestigationalProtein Based Therapies

Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients...

Mechanism: Pharmacologically active on Interleukin-3 receptor subunit alpha
Curator reviewed
Code names: CSL-362 · JNJ-56022473

Resolves to

Compound

UNIIX8JR0I7JE1CAS1826831-79-1

Targets

P26951IL3RA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Talacotuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account